Why the study?
Anthracycline cardiotoxicity in ALL is dose-limiting and thought to begin at first exposure despite presenting years later; this study aimed to determine the timing of initial damage and cardiotoxicity.
Does anthracycline chemotherapy induce early subclinical cardiotoxicity detectable by TDI and STE in children with acute lymphoblastic leukemia?
Population
13 children with newly diagnosed intermediate-risk precursor B cell ALL
Comparison
Assessments before chemotherapy vs after induction vs at the end of reinduction
Design
Prospective study
Follow-up
End of the reinduction phase
Authors
Loading...
May support TDI/STE monitoring for early subclinical changes in pediatric ALL; leaves open prognostic value and practice impact.
Does anthracycline chemotherapy induce early subclinical cardiotoxicity detectable by TDI and STE in children with acute lymphoblastic leukemia?
Subclinical anthracycline-induced cardiotoxicity occurs early during induction therapy in children with ALL and can be detected by tissue Doppler and speckle-tracking echocardiography before conventional echocardiographic changes appear.
Bilir et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: